Please use this identifier to cite or link to this item: http://conacyt.repositorioinstitucional.mx/jspui/handle/1000/7553
Omicron variant escapes therapeutic mAbs contrary to eight prior main VOC
Céline Boschi
Philippe Colson
Audrey Bancod
VALERIE MOAL
Bernard La Scola
Acceso Abierto
Atribución-NoComercial
https://doi.org/10.1101/2022.01.03.474769
https://www.biorxiv.org/content/10.1101/2022.01.03.474769v1
Monocolonal antibodies (mAbs) are currently used for active immunization of COVID-19 in immunocompromised patients. We herein show that in spite there are variations in susceptibility to available mAbs that are authorized for clinical use in France tested on the original B.1.1 virus and 9 variants of concern or of interest, the cocktail casirivimab/imdevimab (REGN-CoV-2) showed a major synergistic effect. However, none of the four mAbs either alone or in combination neutralized the new Omicron variant. Our data strongly warrant a reinforcement of protective measures against infection for immunocompromised patients.
medRxiv and bioRxiv
03-01-2022
Preimpreso
www.biorxiv.org
Inglés
Epidemia COVID-19
Público en general
VIRUS RESPIRATORIOS
Versión publicada
publishedVersion - Versión publicada
Appears in Collections:Artículos científicos

Upload archives